STOCK TITAN

Sohm Inc - SHMN STOCK NEWS

Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.

About Sohm Inc. (OTC PINK: SHMN)

Sohm Inc. is a dynamic pharmaceutical, nutraceutical, and biotechnology company specializing in the development, manufacturing, and commercialization of innovative solutions across multiple healthcare domains. With a diverse portfolio that includes generic drugs, gene editing technologies, and precision medicine applications, Sohm is committed to advancing scientific research and improving patient outcomes globally.

Core Business Areas

  • Pharmaceuticals: Sohm manufactures and markets a wide range of generic drugs covering numerous therapeutic categories. These products aim to provide cost-effective healthcare solutions while maintaining high-quality standards.
  • Biotechnology: The company is at the forefront of genome editing technologies with its proprietary ABBIE system (A Binding Based Integrase Enzyme). ABBIE offers precise and safe genetic modifications without inducing double-stranded DNA breaks, positioning Sohm as a key innovator in the field.
  • Nutraceuticals and Cosmeceuticals: Sohm also develops and markets nutraceutical and cosmeceutical products, including skincare treatments for acne, anti-aging, and exfoliation, catering to both domestic and international markets.

Innovative Technologies

At the heart of Sohm’s biotechnology division is the ABBIE genome editing technology. Unlike traditional CRISPR-Cas9 methods, ABBIE utilizes a retroviral integrase linked to a guide DNA binding domain, enabling precise and efficient integration of genetic sequences. This platform is designed for applications in gene therapy, synthetic biology, and regenerative medicine. Sohm’s ABBIE kits provide researchers with off-the-shelf solutions for faster, more efficient genome editing, reducing costs and experimental timelines.

Strategic Collaborations

Sohm has established strategic partnerships with leading institutions, including Stanford University and Coastar Therapeutics, to further its research and development initiatives. These collaborations aim to enhance Sohm’s capabilities in cell engineering, drug delivery systems, and genome editing technologies, thereby expanding its impact in the biotechnology sector.

Market Position and Competitive Edge

Operating in a highly competitive industry, Sohm differentiates itself through its innovative ABBIE technology, which addresses limitations of traditional genome editing methods. The company’s focus on precision, safety, and scalability positions it as a significant player in the global biotechnology market. Additionally, Sohm’s expanding intellectual property portfolio, including patents in Japan, underscores its commitment to technological leadership.

Commitment to Excellence

Sohm’s team comprises distinguished scientists and industry experts dedicated to advancing healthcare solutions. Recent appointments, such as Dr. Tetsuya Kawamura and Dr. Wei Zhu, highlight the company’s emphasis on scientific excellence and strategic growth. Through continuous innovation and strategic partnerships, Sohm aims to contribute to transformative advancements in medicine and biotechnology.

Rhea-AI Summary
SOHM, Inc. (SHMN) collaborates with Coastar Therapeutics to advance genome editing technology using innovative drug delivery systems. The partnership aims to enhance gene editing efficiency and safety through the integration of Coastar's red blood cell membrane derived carriers with SOHM's ABBIE genome editing technology, offering new possibilities for gene therapy and precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces filing of provisional patent application for ABBIE 'Smart Gene-Editing' platform. The gene-editing market was valued at $5.3 billion in 2023 and is expected to grow to $10.8 billion by 2028. The company aims to resolve off-target gene-editing limitations with ABBIE, utilizing the latest enzymes, guide RNAs, and graphene-based nanomaterials. ABBIE's technology aims to improve precision, reduce immune response, and extend applications beyond human health, revolutionizing genome editing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
none
-
News
Rhea-AI Summary
SOHM, Inc. (SHMN) announced its business outlook for 2024, detailing market backgrounds, business strategies, and revenue expectations for its OTC Self-care, Branded Generics, CDMO Services, and Biotech Gene-Editing Kit business units.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
none
Rhea-AI Summary
SOHM, Inc. (SHMN) announces the opening of a new CDMO GMP manufacturing facility in Carlsbad, California, to meet the growing demand for its pharmaceutical, nutraceutical, and cosmeceutical products. The facility will have an initial daily capacity of 500 gallons and aims to complete the engineering batches produced in the San Diego facility by Q1 2024. The company's strategic plan to enhance production capacity and efficiency aligns with the expanding bio and pharma CDMO market, which is expected to grow to $309 billion by 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
SOHM, Inc. (OTC PINK: SHMN) announces the launch of 13 new SOHM Nutrients’ Brand Chewables, targeting the global vitamin gummies market. The global vitamins market, valued at $6.84 billion in 2022, is expected to reach $18.76 billion by 2031, with a CAGR of 12.06% between 2023-2031. The new chewables offer bone health, skin health, immune boost, mineral replenishment, and sleep aid, featuring convenience, taste, and sought-after ingredients. They will be available for retail and bulk purchases through Amazon.com and the company’s Direct-to-Consumers Website at competitive prices. Dr. David Aguilar, COO of SOHM, anticipates a significant impact on sales, with plans to announce additional OTC Self-care products launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none
-
Rhea-AI Summary
SOHM, Inc. announces collaboration with University of Arizona Center for Innovation to develop ABBIE gene-editing kit technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
Rhea-AI Summary
SOHM, Inc. has acquired ABBIE, a gene-editing platform, positioning itself in the $5.3 billion gene-editing market. The gene-editing market is expected to grow to $10.8 billion by 2028. ABBIE is undergoing development to become high-quality cell engineering kits. Revenue can be generated immediately through licensing and gene-editing kits to be released in 2024. ABBIE is expected to reach in-human trial by 2025. ABBIE was acquired for $10 million from CGA 369. ABBIE's development will be presented at scientific conferences in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
SOHM, Inc. appoints Wm. Dewey Rushing as Vice President-Quality, bringing valuable expertise in pharmaceutical quality validation and compliance. Rushing's experience will be valuable as the company diversifies its portfolio and expands to new markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
-
Rhea-AI Summary
SOHM, Inc. appoints Dr. Krishna Bhat as Chief Medical Advisor, bringing valuable expertise in cardiology. Dr. Bhat's experience will support the planned acquisition of ABBIE Technology and its innovative patents, clinical trials, diagnostic kits, and cardiac treatments. Dr. Bhat is a renowned Clinical and Interventional Cardiologist with over 35 years of practice and has authored 16 medical scientific publications. The acquisition of ABBIE Technology and the development of the San Diego plant are expected to create new opportunities and increase revenues for SOHM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management

FAQ

What is the current stock price of Sohm (SHMN)?

The current stock price of Sohm (SHMN) is $0.0005 as of March 3, 2025.

What is the market cap of Sohm (SHMN)?

The market cap of Sohm (SHMN) is approximately 1.5M.

What does Sohm Inc. specialize in?

Sohm Inc. specializes in pharmaceuticals, nutraceuticals, cosmeceuticals, and innovative genome editing technologies like the ABBIE system.

What is ABBIE technology?

ABBIE is Sohm’s proprietary genome editing system that enables precise and safe genetic modifications without inducing double-stranded DNA breaks.

How does Sohm generate revenue?

Sohm generates revenue through the sale of generic drugs, ABBIE genome editing kits, licensing agreements, and strategic partnerships.

Who are Sohm’s key collaborators?

Sohm collaborates with institutions like Stanford University and Coastar Therapeutics to advance its research and technology development.

What makes Sohm’s ABBIE technology unique?

ABBIE technology avoids double-stranded DNA breaks, offering safer and more efficient genome editing compared to traditional CRISPR methods.

What industries does Sohm operate in?

Sohm operates in pharmaceuticals, biotechnology, nutraceuticals, and cosmeceuticals, serving both domestic and international markets.

What is Sohm’s market position?

Sohm is a growing player in the biotechnology sector, distinguished by its innovative ABBIE technology and expanding intellectual property portfolio.

What are Sohm’s recent achievements?

Recent achievements include collaborations with Stanford University, patent allowances in Japan, and the launch of ABBIE genome editing kits.

What are Sohm’s nutraceutical and cosmeceutical products?

Sohm offers skincare products for acne, anti-aging, and exfoliation, catering to both domestic and international markets.

What challenges does Sohm face?

Sohm faces challenges like regulatory hurdles, competition from CRISPR technologies, and the need for continuous innovation in a competitive market.
Sohm Inc

OTC:SHMN

SHMN Rankings

SHMN Stock Data

1.53M
1.58B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Corona